• Rémi Varin, Shahsultan Mirshahi, Pezhman Mirshahi, Christophe Klein, Jovid Jamshedov, Jean Chidiac, Elisabeth Perzborn, Massoud Mirshahi, Claudine Soria, and Jeannette Soria.
• UMRS 872 INSERM, Université Pierre et Marie Curie Paris VI and Université René Descartes, Paris, France.
• Thromb. Res. 2013 Mar 1; 131 (3): e100-9.

IntroductionDefective thrombolysis, a thrombotic risk factor, can be attributed to the formation of a compact clot poorly accessible to fibrinolytic enzymes. Venous thrombi, rich in red blood cells (RBCs), and arterial thrombi containing various amounts of RBCS, plasma and whole blood (WB) clot permeability and degradability were compared. The effect of rivaroxaban, a potent direct factor Xa inhibitor, was also evaluated.Materials And MethodsFibrin permeability was determined by flow measurement through the clot. Clot degradability was evaluated by the amount of D-dimer generated by clot perfusion with plasminogen and tissue plasminogen activator. Fibrin clot structure was assessed by confocal microscopy.ResultsWB clot permeability (KS) and degradability were 6.7- and 38-fold lower, respectively, compared with plasma clots. This is attributed to 1) occlusion of fibrin pores by RBCs and 2) a consistent increase in thrombin generation due to platelets and RBCs inducing formation of a tighter clot. Rivaroxaban added to plasma or WB before clotting, in reducing thrombin generation, led to the formation of a looser clot that is more degradable by fibrinolytic enzymes. Permeability and degradability of whole blood clots formed in the presence of rivaroxaban were very similar to those of plasma clots.ConclusionThe resistance to fibrinolysis of WB clots was reduced considerably when clots were formed with rivaroxaban. These results may have implications for the development of antithrombotic agents.Copyright © 2012 Elsevier Ltd. All rights reserved.

37 keywords...

hide…